Table of Contents
EXECUTIVE SUMMARY
A detailed and comprehensive overview of current financial position, company
strategy, product and pipeline analysis.
THERAPEUTIC AREA FOCUS
- Key product analysis and forecasting
- Respiratory
- Combivent (ipratropium bromide+albuterol)
- Spiriva (tiotropium bromide)
- Cardiovascular
- Aggrenox (dypyridamole+acetylsalicylic acid)
- Micardis (telmisartan)
- Pradaxa (dabigatran)
- Urology
- Flomax/Alna (tamsulosin)
- Central Nervous System
- Cymbalta/Xeristar (duloxetine)
- Sifrol/Mirapex/Mirapexin (pramipexole)
- Virology
- Aptivus (tipranavir)
- Viramune (nevirapine)
OPERATIONAL DATA
- A wealth of background and detail
- A full 5-year financial performance assessment
- Key corporate events
- Key agreements
- Infrastructure
- Subsidiaries and joint ventures
| 
View Cart
